Multivariate analysis
. | Days 18-60 . | Days 61-120 . | Days 121-365 . | More than 1 year . | ||||
---|---|---|---|---|---|---|---|---|
P . | RR . | P . | RR . | P . | RR . | P . | RR . | |
First-line therapy | ||||||||
Age* | .037 | 1.20 | .001 | 1.39 | <.001 | 1.40 | .513 | |
FLT3-LM | .039 | 1.82 | .245 | 1.37 | .099 | 1.35 | .583 | |
NPM1 level† | .097 | 0.021 | .021 | 1.10 | < .001 | 1.12 | < .001 | 1.15 |
After second-line therapy | ||||||||
FLT3* | na | na | na | na | .022 | 14.989 | ns | ns |
NPM1 level* | na | na | na | na | .012 | 0.398 | .024 | 1.266 |
After alloSCT | ||||||||
Age* | na | na | .819 | na | .515 | ns | na | na |
NPM1 ratio† | na | na | .065 | 1.065 | .024 | 1.062 | na | na |
. | Days 18-60 . | Days 61-120 . | Days 121-365 . | More than 1 year . | ||||
---|---|---|---|---|---|---|---|---|
P . | RR . | P . | RR . | P . | RR . | P . | RR . | |
First-line therapy | ||||||||
Age* | .037 | 1.20 | .001 | 1.39 | <.001 | 1.40 | .513 | |
FLT3-LM | .039 | 1.82 | .245 | 1.37 | .099 | 1.35 | .583 | |
NPM1 level† | .097 | 0.021 | .021 | 1.10 | < .001 | 1.12 | < .001 | 1.15 |
After second-line therapy | ||||||||
FLT3* | na | na | na | na | .022 | 14.989 | ns | ns |
NPM1 level* | na | na | na | na | .012 | 0.398 | .024 | 1.266 |
After alloSCT | ||||||||
Age* | na | na | .819 | na | .515 | ns | na | na |
NPM1 ratio† | na | na | .065 | 1.065 | .024 | 1.062 | na | na |